comprehensive -WSS

comprehensive

author：entertainment 2025-09-03 09:34:14 - browse：3

What’s a radiopharmaceutical? What does it mean to be Zepbound? And who’s to blame for a biotech blow-up?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. As so-called radiopharmaceuticals make headlines in oncology, we explore their fascinating scientific backstory and the biotech gold rush to make them. We also discuss the approval of Eli Lilly’s curiously named treatment for obesity, the latest implosion for a promising biotech company, and some news in the world of shareholder activism.

For more on what we cover, here’s the radiopharmaceuticals story; here’s the news on Lilly; here’s more on Ventyx Biosciences; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Medicare details structure of new drug price negotiation program
Next article： What PEPFAR has meant on the ground in Ukraine

hotspot

WSS

Americans' trust in science, scientist continues decline: Report

Americans' trust in science, scientist continues decline: Report

CMS should re

How to make over

FDA advisory panel to debate high blood pressure devices

How to make over

leisure time

comprehensive

focus

Guidelines to prevent youth baseball injuries need more muscle

Pregnancy discrimination could be enabled by AI

State Dept. review finds Biden bears some blame for Afghanistan failures

Spinal cord stimulation reduces pain in amputees, study finds

Wildfire smoke exposes gaps in outdoor worker protections

Americans' trust in science, scientist continues decline: Report

BioMarin wins approval for gene therapy to treat hemophilia A

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Cancer drug shortages should be causing more outrage

DeSantis wants to import drugs. Biden’s FDA blasted his plan

knowledge

Roche to buy Carmot Therapeutics, developer of obesity drugs

In diabetes hearing, Sanders takes on a new foe: food makers

FDA needs staff influx to meet gene therapy needs, Marks says

Pfizer plans to depart BIO

Why sickle cell disease is getting the first CRISPR treatment

Patients' immediate access to test results puts radiologists in a bind

hotspot

focus

hotspot

Wikipedia